Literature DB >> 19651279

Six-minute walk test in patients with Down syndrome: validity and reproducibility.

Jeroen C Vis1, Hanneke Thoonsen, Marielle G Duffels, Rianne A de Bruin-Bon, Sylvia A Huisman, Arie P van Dijk, Elke S Hoendermis, Rolf M Berger, Berto J Bouma, Barbara J Mulder.   

Abstract

OBJECTIVES: To examine the validity of the six-minute walk test (6MWT) as a tool to evaluate functional exercise performance in patients with Down syndrome (DS).
DESIGN: Comparison of the six-minute walk distance (6MWD) in 2 distinct groups of DS patients: with and without severe cardiac disease. To test reproducibility, a group of patients with DS performed the 6MWT twice.
SETTING: Tertiary referral centers for patients with congenital heart defects and outpatient clinics for people with intellectual disabilities. PARTICIPANTS: Adult patients with DS with (n=29) and without (n=52) severe cardiac disease categorized by cardiac echocardiography.
INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURE: Distance walked on the 6MWT.
RESULTS: The mean 6MWD in the group with severe cardiac disease was 289+/-104 m and in the group without severe cardiac disease 280+/-104 m (P=.70). Older age, female sex, and severe level of intellectual disability were all found to be independently and significantly correlated with a lower 6MWD (r=.67, P<.001). The paired 6MWD was not significantly different (310+/-88 m vs 317+/-85 m; P=.40) in patients who performed the 6MWT twice. The coefficient of variation was 11%.
CONCLUSIONS: The 6MWD between the 2 groups was not significantly different. However, the walking distance inversely correlated with the level of intellectual disability. Therefore, the 6MWT is not a valid test to examine cardiac restriction in adult patients with DS.

Entities:  

Mesh:

Year:  2009        PMID: 19651279     DOI: 10.1016/j.apmr.2009.02.015

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  9 in total

1.  Adult patients with pulmonary arterial hypertension due to congenital heart disease: a review on advanced medical treatment with bosentan.

Authors:  Mark J Schuuring; Jeroen C Vis; Marielle G Duffels; Berto J Bouma; Barbara Jm Mulder
Journal:  Ther Clin Risk Manag       Date:  2010-09-07       Impact factor: 2.423

2.  Effects of repeated treadmill testing and electrical stimulation on post-stroke gait kinematics.

Authors:  Louis N Awad; Trisha M Kesar; Darcy Reisman; Stuart A Binder-Macleod
Journal:  Gait Posture       Date:  2012-07-15       Impact factor: 2.840

3.  Intensity and physiological responses to the 6-minute walk test in middle-aged and older adults: a comparison with cardiopulmonary exercise testing.

Authors:  E F Sperandio; R L Arantes; A C Matheus; R P Silva; V T Lauria; M Romiti; A R T Gagliardi; V Z Dourado
Journal:  Braz J Med Biol Res       Date:  2015-02-24       Impact factor: 2.590

4.  Treatment of pulmonary arterial hypertension in congenital heart disease in Singapore versus the Netherlands: age exceeds ethnicity in influencing clinical outcome.

Authors:  A C M J van Riel; M J Schuuring; I D van Hessen; A P J van Dijk; E S Hoendermis; J W Yip; B J M Mulder; B J Bouma
Journal:  Neth Heart J       Date:  2016-06       Impact factor: 2.380

5.  Feasibility and Reliability of a Physical Fitness Test Battery in Individuals with Down Syndrome.

Authors:  Ruth Cabeza-Ruiz; Francisco Javier Alcántara-Cordero; Isaac Ruiz-Gavilán; Antonio Manuel Sánchez-López
Journal:  Int J Environ Res Public Health       Date:  2019-07-27       Impact factor: 3.390

6.  An Evaluation of Prediction Equations for the 6 Minute Walk Test in Healthy European Adults Aged 50-85 Years.

Authors:  Michael J Duncan; Jorge Mota; Joana Carvalho; Alan M Nevill
Journal:  PLoS One       Date:  2015-09-29       Impact factor: 3.240

7.  Long-term results of treatment with bosentan in adult Eisenmenger's syndrome patients with Down's syndrome related to congenital heart disease.

Authors:  Roberto Crepaz; Cristina Romeo; Donato Montanaro; Stefano De Santis
Journal:  BMC Cardiovasc Disord       Date:  2013-09-18       Impact factor: 2.298

8.  Efficacy and safety of oral sildenafil in children with Down syndrome and pulmonary hypertension.

Authors:  Maurice Beghetti; Andrzej Rudzinski; Min Zhang
Journal:  BMC Cardiovasc Disord       Date:  2017-07-04       Impact factor: 2.298

9.  Management dilemmas in pulmonary arterial hypertension associated with congenital heart disease.

Authors:  R Condliffe; P Clift; K Dimopoulos; R M R Tulloh
Journal:  Pulm Circ       Date:  2018-07-23       Impact factor: 3.017

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.